| Autor: |
Dorozhenok IY; Sechenov First Moscow Medical University (Sechenov University), Moscow, Russia.; Mental Health Research Center, Moscow, Russia. |
| Jazyk: |
ruština |
| Zdroj: |
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2022; Vol. 122 (12), pp. 63-67. |
| DOI: |
10.17116/jnevro202212212163 |
| Abstrakt: |
The review is devoted to the actual problem of anti-relapse therapy for schizophrenia. The features of the use, efficiency, tolerability and safety of typical and atypical antipsychotics are discussed. The possibilities of using atypical antipsychotics of the third generation - partial dopamine receptor agonists - on the aripiprazole model are considered. According to numerous studies, aripiprazole, due to its unique pharmacological profile and combination of clinical factors, is the drug of first choice for anti-relapse supportive therapy of schizophrenia. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
